Embryonic stem cell research finally reaches year zero
This article was originally published in Clinica
Executive Summary
The biggest single step so far on the path towards commercially-available human embryonic stem cell (hESC) therapies was taken last week when researchers in the US began a trial of an experimental therapy in spinal injury patients.